Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial

Elena Peeva; Emma Guttman-Yassky; Anindita Banerjee; Rodney Sinclair; Lori Ann Cox; Linda Zhu; Hua Zhu; Michael Vincent; Brett King

doi:10.1016/j.jaad.2021.12.008

Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial

Elena Peeva
, Emma Guttman-Yassky
, Anindita Banerjee
, Rodney Sinclair
, Lori Ann Cox
, Linda Zhu
, Hua Zhu
, Michael Vincent
, Brett King

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Original language	English
Pages (from-to)	390-393
Number of pages	4
Journal	Journal of the American Academy of Dermatology
Volume	87
Issue number	2
DOIs	https://doi.org/10.1016/j.jaad.2021.12.008
State	Published - Aug 2022

Access to Document

10.1016/j.jaad.2021.12.008

Cite this

Peeva, E., Guttman-Yassky, E., Banerjee, A., Sinclair, R., Cox, L. A., Zhu, L., Zhu, H., Vincent, M., & King, B. (2022). Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial. Journal of the American Academy of Dermatology, 87(2), 390-393. https://doi.org/10.1016/j.jaad.2021.12.008

@article{3ce0fbbd58bd4a379b0df41c4a9c7933,

title = "Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial",

author = "Elena Peeva and Emma Guttman-Yassky and Anindita Banerjee and Rodney Sinclair and Cox, \{Lori Ann\} and Linda Zhu and Hua Zhu and Michael Vincent and Brett King",

note = "Funding Information: Funding sources: The study was funded by Pfizer. Pfizer designed the study in consultation with all authors, and Pfizer collected the data.Dr Guttman-Yassky has received institutional grants from AbbVie, Celgene, Eli Lilly, Janssen, Dermavant, DS Biopharma, Novartis, Pfizer, Regeneron, Glenmark, Galderma, Asana Biosciences, Innovaderm, Dermira, LEO Pharma, Novan, Kyowa Kirin, Concert, Union Therapeutics, and Ralexar and serves as a consultant for Sanofi, Regeneron, Celgene, Dermira, Galderma, Glenmark, Novartis, Pfizer, LEO Pharma, AbbVie, Eli Lilly, Kyowa Kirin, Mitsubishi Tanabe, Asana Biosciences, Union Therapeutics, Allergan, Amgen, Concert, DS Biopharma, EMD Serono, Escalier, and FLX Bio. Dr Sinclair provided professional services to Novartis, Merck \& Co, Janssen, Samson Clinical, Pfizer, Eli Lilly and Company, Arena, Dermira, Astra Zeneca, Sanofi, AbbVie, Galderma, Principia, Reistone Pharma, Aclaris, and Sun Pharma. Dr Cox is a paid consultant to Pfizer. Dr King has served on advisory boards and/or is a consultant and/or a clinical trial investigator for AbbVie, Aclaris Therapeutics Inc, AltruBio Inc, Almirall, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences Inc, Eli Lilly and Company, Incyte Corp, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio. He is on speaker bureaus for Pfizer Inc, Regeneron, and Sanofi Genzyme. Drs Peeva, Banerjee, L. Zhu, H. Zhu, and Vincent are employees and stockholders of Pfizer. Funding Information: Funding sources: The study was funded by Pfizer . Pfizer designed the study in consultation with all authors, and Pfizer collected the data. ",

year = "2022",

month = aug,

doi = "10.1016/j.jaad.2021.12.008",

language = "English",

volume = "87",

pages = "390--393",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

number = "2",

}

Peeva, E, Guttman-Yassky, E, Banerjee, A, Sinclair, R, Cox, LA, Zhu, L, Zhu, H, Vincent, M & King, B 2022, 'Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial', Journal of the American Academy of Dermatology, vol. 87, no. 2, pp. 390-393. https://doi.org/10.1016/j.jaad.2021.12.008

Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial. / Peeva, Elena; Guttman-Yassky, Emma; Banerjee, Anindita et al.
In: Journal of the American Academy of Dermatology, Vol. 87, No. 2, 08.2022, p. 390-393.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial

AU - Peeva, Elena

AU - Guttman-Yassky, Emma

AU - Banerjee, Anindita

AU - Sinclair, Rodney

AU - Cox, Lori Ann

AU - Zhu, Linda

AU - Zhu, Hua

AU - Vincent, Michael

AU - King, Brett

N1 - Funding Information: Funding sources: The study was funded by Pfizer. Pfizer designed the study in consultation with all authors, and Pfizer collected the data.Dr Guttman-Yassky has received institutional grants from AbbVie, Celgene, Eli Lilly, Janssen, Dermavant, DS Biopharma, Novartis, Pfizer, Regeneron, Glenmark, Galderma, Asana Biosciences, Innovaderm, Dermira, LEO Pharma, Novan, Kyowa Kirin, Concert, Union Therapeutics, and Ralexar and serves as a consultant for Sanofi, Regeneron, Celgene, Dermira, Galderma, Glenmark, Novartis, Pfizer, LEO Pharma, AbbVie, Eli Lilly, Kyowa Kirin, Mitsubishi Tanabe, Asana Biosciences, Union Therapeutics, Allergan, Amgen, Concert, DS Biopharma, EMD Serono, Escalier, and FLX Bio. Dr Sinclair provided professional services to Novartis, Merck & Co, Janssen, Samson Clinical, Pfizer, Eli Lilly and Company, Arena, Dermira, Astra Zeneca, Sanofi, AbbVie, Galderma, Principia, Reistone Pharma, Aclaris, and Sun Pharma. Dr Cox is a paid consultant to Pfizer. Dr King has served on advisory boards and/or is a consultant and/or a clinical trial investigator for AbbVie, Aclaris Therapeutics Inc, AltruBio Inc, Almirall, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences Inc, Eli Lilly and Company, Incyte Corp, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio. He is on speaker bureaus for Pfizer Inc, Regeneron, and Sanofi Genzyme. Drs Peeva, Banerjee, L. Zhu, H. Zhu, and Vincent are employees and stockholders of Pfizer. Funding Information: Funding sources: The study was funded by Pfizer . Pfizer designed the study in consultation with all authors, and Pfizer collected the data.

PY - 2022/8

Y1 - 2022/8

UR - https://www.scopus.com/pages/publications/85122138393

U2 - 10.1016/j.jaad.2021.12.008

DO - 10.1016/j.jaad.2021.12.008

M3 - Article

AN - SCOPUS:85122138393

SN - 0190-9622

VL - 87

SP - 390

EP - 393

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 2

ER -